Antiplatelet Therapy in The High-Risk Cardiovascular Patient

With 1.7 million hospital discharges per year, acute coronary syndrome (ACS) constitutes a significant burden of health. Learn the classes of anti-platelet therapies, review clinical trial data, learn about guideline-based use, and hear case presentations.

Acute Coronary Syndrome (ACS)
Member Cost: $0Non-member Cost: $0
Credits: 1.0 CE contact hours, 1.0 CE pharmacology hours

Course Overview

Register

Antiplatelet Therapy and the Post-ACS Patient

With 1.7 million hospital discharges per year, acute coronary syndrome (ACS) constitutes a significant burden of health. Learn the classes of anti-platelet therapies, review clinical trial data, learn about guideline-based use, and hear case presentations.

Learning Objectives

Upon completion of this continuing education course, participants will be able to:

  • Identify the guidelines for dual antiplatelet therapy in the post-ACS patient.
  • Identify the indications in which the risk of atherosclerotic cardiovascular disease outweighs the risk of bleeding, justifying the addition of a PAR-1 antagonist to standard dual oral antiplatelet therapy.
  • List three classes of antiplatelet agents.

Faculty

  • David Anderson MS, MD, FACC, FSCAI